Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGD-PET/MR for Vestibular Schwannoma Growth Prediction
NCT03393689Phase 2Unknown
- Sponsor
- Rigshospitalet
- Start
- Jan 2018
- Primary completion
- Jan 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-NODAGA-E(c[RGDyK])2 in vestibular schwannoma (VS), sponsored by Rigshospitalet. Status: unknown.
02
Drugs
68Ga-NODAGA-E(c[RGDyK])2
03
Conditions
vestibular schwannoma (VS)
Beyond the preview
Go deeper on NCT03393689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393689.